Hyundai Bioscience Co., Ltd. (KOSDAQ:048410)
6,390.00
-190.00 (-2.89%)
Sep 1, 2026, 3:30 PM KST
Hyundai Bioscience Revenue
Hyundai Bioscience had revenue of 520.40M KRW in the quarter ending June 30, 2026, with 56.32% growth. This brings the company's revenue in the last twelve months to 3.32B, up 77.96% year-over-year. In the year 2025, Hyundai Bioscience had annual revenue of 3.52B, down -76.63%.
Revenue (ttm)
3.32B
Revenue Growth
+77.96%
P/S Ratio
191.22
Revenue / Employee
48.13M
Employees
69
Market Cap
634.99B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3.52B | -11.53B | -76.63% |
| Dec 31, 2024 | 15.05B | 5.57B | 58.73% |
| Dec 31, 2023 | 9.48B | 1.63B | 20.76% |
| Dec 31, 2022 | 7.85B | -1.39B | -15.04% |
| Dec 31, 2021 | 9.24B | -3.27B | -26.14% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| GC Corp. | 2.49T |
| Chabiotech | 1.31T |
| Medy-Tox | 251.08B |
| Onconic Therapeutics | 82.17B |
| MEDIPOST | 74.84B |
| Komipharm International | 53.02B |
| Pharmicell | 23.94B |
| SillaJen | 10.92B |